Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp49893_8k.htm |
Exhibit 99.1
|
Press Release
|
 |
|
www.shire.com
|
Total Voting Rights
October 1, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with the Financial Conduct Authority's (the “FCA”) Disclosure and Transparency Rule 5.6.1R, notifies the market of the following:
At close of business on September 30, 2014, the Company’s issued ordinary share capital comprised 589,562,539 ordinary shares of 5 pence each with voting rights and a further 9,019,832 ordinary shares held in treasury.
Therefore the total number of voting rights in the Company is 589,562,539. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Jeff Poulton
|
jpoulton@shire.com
|
+1 781 482 0945
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
|
Media
|
||
|
Stephanie Fagan
|
sfagan@shire.com
|
+1 781 482 0460
|
|
Gwen Fisher
|
gfisher@shire.com
|
+1 484 595 9836
|
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX